PEG-MGF (PEGylated Mechano Growth Factor) – User Manual & Research Protocol Guide

PEG-MGF is a PEGylated form of Mechano Growth Factor designed for extended stability and prolonged activity in research environments. It is studied for its role in muscle repair signaling, cellular proliferation, and adaptive response to mechanical stress with extended exposure characteristics compared to non-PEGylated variants.

Research Applications

Muscle repair and regeneration studies
Cell proliferation and differentiation research
Extended-activity growth factor investigations
Adaptive response to mechanical stress models
Tissue recovery and anabolic signaling research

Disclaimer: PEG-MGF is for research and experimental use only and is not FDA-approved for therapeutic use.

Lyophilized Powder

Freeze-dried PEG-MGF intended for reconstitution prior to use in research settings.

Reconstituted Solution

Prepared liquid form used as an injectable research preparation after proper reconstitution.

PEG-MGF is studied for its ability to:

• Provide prolonged exposure to growth factor signaling pathways
• Support muscle satellite cell activation in experimental models
• Promote cellular repair and regeneration mechanisms
• Enhance recovery-related signaling following mechanical stress
• Extend peptide stability through PEGylation

Observed effects are derived from preclinical and investigational research settings.

Subcutaneous (SC) – Standard Research Model

Typical research protocols use 200–400 µg per administration, generally 2–3 times weekly, often in extended-activity research models.

Short-Course Research

Some studies use 200–300 µg weekly in limited-duration protocols.

Protocol-Based Study

Dosing and frequency may be protocol-dependent, determined by the specific study design and objectives.

Important

There is no approved human dosage. The ranges above reflect commonly cited research patterns only.

Initiation

A 1-week phase used for initial response observation at the start of the study.

Active Study Phase

Typically 4–8 weeks, focused on evaluating regeneration pathways.

Rest Period

A 4+ week interval between research cycles to allow recovery and system reset.

Note

Cycle duration may vary depending on study design and research endpoints.

Supplies

Sterile bacteriostatic water
Sterile syringe
Alcohol swabs

General Procedure

1. Clean vial stopper with alcohol.
2. Add bacteriostatic water to desired concentration.
   Example: 2 mg vial + 1 mL → 2 mg/mL
3. Swirl gently to dissolve (do not shake).
4. Refrigerate at 2–8°C after reconstitution.
5. Use within 2–4 weeks or per protocol.

Maintain sterile handling technique
Rotate administration sites in injectable models
Document preparation concentration and date
Follow institutional research standards

Lyophilized Powder

Store in a cool, dry environment to maintain stability, with a shelf life of up to 12 months.

Reconstituted Solution

Keep refrigerated at 2–8°C and use within 2–4 weeks after preparation.

Protection Guidelines

Protect from light, heat, and contamination to preserve quality.

Safety Note

Discard the solution if it becomes cloudy or discolored, as this may indicate contamination or degradation.

Research use only
Not for therapeutic application
Human safety outside controlled research is not established
Potential research observations: injection-site irritation
Maintain sterile technique
Keep out of reach of unauthorized personnel

Peptide: PEG-MGF (PEGylated Mechano Growth Factor)
Category: Performance & Recovery Research
Delivery: Injectable research model
Typical Investigational Range: 200–400 µg per administration
Cycle: 4–8 week research protocols
Storage: Refrigerated after reconstitution